GlassScriptPhysician profile
Cody Lee Milliman
NPI 1730615980
$6,538.53
in general payments reported to CMS, 2019-2025
56 companies · $2,313 in 2025
The $2,313 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $605 · 2023: $1,149 · 2024: $2,354 · 2025: $2,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,755 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,754.70 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Secura Bio, INC. | $699.62 | 2022-2023 | Copiktra |
| Daiichi Sankyo INC. | $485.98 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $398.09 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $388.01 | 2023-2025 | Imfinzi, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $312.04 | 2023-2025 | |
| Celgene Corporation | $289.33 | 2023-2025 | Reblozyl |
| Abbvie INC. | $277.33 | 2024-2025 | |
| Janssen Biotech, INC. | $276.63 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Genentech USA, INC. | $236.45 | 2023-2025 | Lunsumio, Polivy, Columvi |
| Genzyme Corporation | $197.51 | 2024-2025 | |
| Seagen INC. | $178.02 | 2022-2023 | Adcetris |
| Merck Sharp & Dohme LLC | $170.68 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| Eisai INC. | $165.97 | 2022-2024 | |
| Array Biopharma INC | $151.02 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Adc Therapeutics America, INC. | $144.04 | 2023-2024 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $134.80 | 2024-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $111.54 | 2024-2025 | Ninlaro, Cuvitru |
| Springworks Therapeutics, INC. | $100.97 | 2024-2025 | Ogsiveo |
| Epizyme, INC. | $99.95 | 2021 | |
| Incyte Corporation | $93.27 | 2024-2025 | Monjuvi, Jakafi |
| Regeneron Healthcare Solutions, INC. | $92.82 | 2023-2025 | Libtayo |
| Pharmacosmos Therapeutics INC. | $91.50 | 2023-2025 | Monoferric, Cosela |
| Recordati_rare_diseases_inc. | $90.18 | 2023-2024 | Sylvant, Panhematin |
| Alexion Pharmaceuticals, INC. | $78.83 | 2024-2025 | Ultomiris |
| Veracyte, INC. | $78.41 | 2023 | |
| Stemline Therapeutics INC. | $74.70 | 2023-2025 | Orserdu |
| Beigene USA, INC. | $72.29 | 2023-2024 | Brukinsa |
| Taiho Oncology, INC. | $70.09 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $68.15 | 2023-2025 | Opdivo, Opdualag |
| Pharmaessentia USA Corporation | $67.66 | 2023-2025 | Besremi |
| Spectrum Pharmaceuticals INC. | $58.43 | 2023-2024 | Rolvedon |
| Tempus Ai, INC | $55.80 | 2024-2025 | Xt Cdx |
| Beone Medicines USA, INC. | $53.22 | 2025 | Brukinsa, Tevimbra |
| Bayer Healthcare Pharmaceuticals INC. | $52.02 | 2025 | |
| Glaxosmithkline, LLC. | $49.00 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Ipsen Biopharmaceuticals, INC | $43.84 | 2024-2025 | Somatuline Depot, Onivyde |
| Sobi, INC | $43.67 | 2024 | |
| Adaptive Biotechnologies Corporation | $40.63 | 2024-2025 | Clonoseq |
| Aveo Pharmaceuticals, INC. | $40.17 | 2025 | |
| Kite Pharma, INC. | $36.71 | 2024-2025 | Yescarta |
| Cumberland Pharmaceuticals, INC. | $36.15 | 2024 | Sancuso |
| Dendreon Pharmaceuticals LLC | $34.90 | 2025 | Provenge |
| Jazz Pharmaceuticals INC. | $31.95 | 2023 | Zepzelca |
| Amgen INC. | $30.01 | 2021-2023 | Kyprolis, Blincyto |
| Fennec Pharmaceuticals, INC. | $24.59 | 2025 | Fyarro |
| Emd Serono, INC. | $24.05 | 2025 | |
| Blueprint Medicines Corporation | $23.77 | 2024 | Ayvakit |
| Rigel Pharmaceuticals, INC. | $23.62 | 2024 | Tavalisse, Rezlidhia |
| Organon LLC | $23.00 | 2025 | |
| Astellas Pharma US INC | $20.38 | 2025 | Padcev |
| G1 Therapeutics, INC. | $18.65 | 2023 | Cosela |
| Servier Pharmaceuticals LLC | $16.69 | 2024 | |
| Apellis Pharmaceuticals, INC. | $16.45 | 2024 | Empaveli |
| Genmab U.S., INC. | $16.33 | 2024 | Tivdak |
| Cti Biopharma Corp. | $15.19 | 2023 | Vonjo |
| Mirati Therapeutics, INC. | $13.43 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Milliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.